QIAGEN (QGEN)
(Delayed Data from NYSE)
$45.81 USD
-0.21 (-0.46%)
Updated Aug 28, 2024 04:00 PM ET
After-Market: $45.79 -0.02 (-0.04%) 7:36 PM ET
3-Hold of 5 3
C Value C Growth A Momentum B VGM
Brokerage Reports
QIAGEN N.V. [QGEN]
Reports for Purchase
Showing records 221 - 240 ( 242 total )
Company: QIAGEN N.V.
Industry: Medical - Biomedical and Genetics
4Q12 Recap - Solid Top-line Driven By Molecular Dx & Applied Testing.
Provider: WEDBUSH SECURITIES INC.
Analyst: KHURSHID Z
Company: QIAGEN N.V.
Industry: Medical - Biomedical and Genetics
3Q12 Pre-conference Call Recap - Sales Solid Likely Due to Dx
Provider: WEDBUSH SECURITIES INC.
Analyst: KHURSHID Z
Company: QIAGEN N.V.
Industry: Medical - Biomedical and Genetics
4Q12 Preview - Expecting a Slight Beat Driven by Late December Disease Activity
Provider: WEDBUSH SECURITIES INC.
Analyst: KHURSHID Z
Company: QIAGEN N.V.
Industry: Medical - Biomedical and Genetics
3Q12 Pre-conference Call Recap - Sales In line - EPS Beats By $0.02 Due to Lower Tax Rate - Acquisitions Perform Fine - BRIC Growth Solid - Maintain NEUTRAL
Provider: WEDBUSH SECURITIES INC.
Analyst: KHURSHID Z
Company: QIAGEN N.V.
Industry: Medical - Biomedical and Genetics
Company: QIAGEN N.V.
Industry: Medical - Biomedical and Genetics
2Q12 Recap - Encouraging Tone Overall - Very Strong Instrument Orders Drive Beat
Provider: WEDBUSH SECURITIES INC.
Analyst: KHURSHID Z
Company: QIAGEN N.V.
Industry: Medical - Biomedical and Genetics
2Q12 First Blush - Sales & EPS Beat Consensus on Strong System Sales
Provider: WEDBUSH SECURITIES INC.
Analyst: KHURSHID Z
Company: QIAGEN N.V.
Industry: Medical - Biomedical and Genetics
Expecting In-line 2Q12 - Sequencing Strategy Intriguing
Provider: WEDBUSH SECURITIES INC.
Analyst: KHURSHID Z
Company: QIAGEN N.V.
Industry: Medical - Biomedical and Genetics
Company: QIAGEN N.V.
Industry: Medical - Biomedical and Genetics
1Q12 First Blush - Decent Top line and EPS Beat vs Consensus - GMs and R&D Better, But SG&A Bloated - Broad Geographic Growth - Staying NEUTRAL
Provider: WEDBUSH SECURITIES INC.
Analyst: KHURSHID Z
Company: QIAGEN N.V.
Industry: Medical - Biomedical and Genetics
1Q12 Financial Preview - Anticipating Slightly Better Results Driven by Personalized Medicine - Still Skeptical on Full Year - Reaffirming NEUTRAL
Provider: WEDBUSH SECURITIES INC.
Analyst: KHURSHID Z
Company: QIAGEN N.V.
Industry: Medical - Biomedical and Genetics
Ok 4Q11 Results Cap Off a Rebuilding Year - Guidance on the Soft Side
Provider: WEDBUSH SECURITIES INC.
Analyst: KHURSHID Z
Company: QIAGEN N.V.
Industry: Medical - Biomedical and Genetics
4Q11 First Blush - Consumables Strength Drives Solid Top Line Beat - EPS Beat Less Impressive - 2012 Guidance a Little Light
Provider: WEDBUSH SECURITIES INC.
Analyst: KHURSHID Z
Company: QIAGEN N.V.
Industry: Medical - Biomedical and Genetics
4Q11 Financial Preview - Expecting Slightly Lower Results - Cautious on HPV Despite North American 4Q11 Tender - No Compelling Reason To Own Here
Provider: WEDBUSH SECURITIES INC.
Analyst: KHURSHID Z
Company: QIAGEN N.V.
Industry: Medical - Biomedical and Genetics
Company: QIAGEN N.V.
Industry: Medical - Biomedical and Genetics
3Q11 First Blush - Lackluster Results - Topline Just Shy on HPV Order Distortion in North America -System Sales Solid - Other Income Drives EPS Beat
Provider: WEDBUSH SECURITIES INC.
Analyst: KHURSHID Z
Company: QIAGEN N.V.
Industry: Medical - Biomedical and Genetics
3Q11 Preview - Expecting Results to Edge Past Consensus - Trimming Estimates and PT on More Challenging Macro & GPRO HPV Approval
Provider: WEDBUSH SECURITIES INC.
Analyst: KHURSHID Z
Company: QIAGEN N.V.
Industry: Medical - Biomedical and Genetics
Company: QIAGEN N.V.
Industry: Medical - Biomedical and Genetics
Company: QIAGEN N.V.
Industry: Medical - Biomedical and Genetics
1Q11 Report Ok; More Positives Than Negatives; 2011 Tailwinds Intact; Back Half Acceleration
Provider: WEDBUSH SECURITIES INC.
Analyst: KHURSHID Z